Viral pathogens and severe acute respiratory syndrome: Oligodynamic Ag + for direct immune intervention

Journal of Nutritional and Environmental Medicine

Volumn 13, Issue 2, 2003, Pages 109-118

  Rentz, Eric J ^a  

^a Physical Medicine Services   (United States)

Author keywords

Antiviral spectrum; Biocompatibility; Capsid; NASA commissioned studies; Oligodynamic Ag+ pharmacokinetics; Oligodynamic colloidal silver; Protein based viral envelope; SARS related coronavirus; Silver speciation; Viral resistance

Indexed keywords

COLLARGOL; OLIGODYNAMIC SILVER ION; SILVER DERIVATIVE; SILVER NITRATE; SULFADIAZINE SILVER; UNCLASSIFIED DRUG;

ADSORPTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; COLLOID; CORONAVIRUS; DISSOCIATION CONSTANT; DRUG FORMULATION; DRUG RESEARCH; ELECTRICITY; HISTORY OF MEDICINE; HUMAN; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS RESISTANCE;

APUS APUS; CORONAVIRUS; RNA VIRUSES;

EID: 0141638733     PISSN: 13590847     EISSN: None     Source Type: Journal    
DOI: 10.1080/13590840310001594061     Document Type: Review

References (99)

1. Bechhold H. Colloids in Biology and Medicine. New York: D. van Nostrand, 1919, 364-76.
2. Clayton GD, Clayton FE. Patty's Industrial Hygiene and Toxicology, 3rd rev. edn. New York: John Wiley & Sons, 1981, 1881-94.
3. Russell AD, Path FR, Hugo WB. Antimicrobial activity and action of silver. Prog Med Chem 1994; 31: 352.
4. Hugo WB. In: Hugo WB, Ayliffe GAF (eds) Principles and Practice of Disinfection, Preservation and Sterilization, 2nd edn. Oxford: Blackwell Scientific, 1992, 3-6.
5. Thompson NR. Comprehensive Inorganic Chemistry. New York: Pergamon Press, 1973, Vol. 5, Chapter 28.
6. Goetz A, Tracy RL, Harris FS. The oligodynamic effect of silver. In: Addicks L (ed.) Silver in Industry. New York: Reinhold Publishing, 1940, 401.
7. Hippocrates. On ulcers, 400 BC; translated by Francis Adams (http://classics.mit.edu/Browse/browse-Hippocrates.html).
8. Cumston CG. History of Medicine. New York, A.A. Knoff, 1926, 216.
9. Crede KSF. Ber Klin Wochenschr 1901; 38: 941.
10. Zhao G, Stevens SE. Multiple parameters for the comprehensive evaluation of the susceptibility of Escherichia coli to the silver ion. BioMetals 1998; 11: 27.
11. Searle AB. The Use of Colloids in Health and Disease. New York: E. P. Dutton, 1919, 83.
12. Thurman RB, Gerba CP. The molecular mechanisms of copper and silver ion disinfection of bacteria and viruses. CRC Crit Rev Environ Control 1989; 301.
13. Thurman RB, Gerba CP. The molecular mechanisms of copper and silver ion disinfection of bacteria and viruses. Paper presented at the First International Conference on Gold and Silver in Medicine, The Silver Institute, Washington, 1989.
14. Bechhold H. Colloids in Biology and Medicine. New York: D. Van Nostrand, 1919, 376.
15. Duhamel BG. Electric metallic colloids and their therapeutic applications. Lancet 13 January, 1912, 90.
16. Searle AB. The Use of Colloids in Health and Disease. New York: E. P. Dutton, 1919, 86.
17. Argos. Merck's Index, 4th edn. Rahway, NJ: Merck & Co., 1930, 91.
18. Chang TW, Weinstein L. Prevention of herpes keratoconjunctivitis in rabbits by silver sulfadiazine. 1975; 8: 677-8.
19. Neo-Protosil. Merck's Index, 4th edn. Rahway, NJ: Merck & Co., 1930, 350.
20. Protargol. Merck's Index, 4th edn. Rahway, NJ: Merck & Co., 1930, 424.
21. Silver fluoride, silver iodate, silver iodide, silver lactate, silver nitrate. Merck's Index, 4th edn. Rahway, NJ: Merck & Co., 1930, 460.
22. Silver protein, silver salicylate, silver sulphate, silver sulphide, silver and potassium cyanide, silver and sodium chloride, silver and sodium thiosulphate, silver and thallium nitrate, silvol. Merck's Index, 4th edn. Rahway, NJ: Merck & Co., 1930, 462.
23. Cliver DO, Sarles WB, Foell WK, Goepfert JM. Biocidal effects of silver. Contract NAS 9-9300 Final Technical Report, University of Wisconsin, Accession Number N70 23888, NASA CR Number CR-108338, February 1970, 4-4-4-6.
24. Mahnel H, Schmidt M. Effect of silver compounds on viruses in water. Zentralbl Baktenol Parasitenk Infektionskr Hyg Abt Orig Reihe B 1986; 182: 381.
25. Cliver DO, Sarles WB, Foell WK, Goepfert JM. Biocidal effects of silver. Contract NAS 9-9300 Final Technical Report, University of Wisconsin, Accession Number N70 23888, NASA CR Number CR-108338, February 1970, Table 4-5, 4-7-4-8.
26. Brigham Young University, Microbiology Department, 13 May 1999. Ron W. Leavitt, PhD, Professor of Microbiology; ref: ASAP 1.25 ppm to 10 ppm concentrate of Ag+.
27. Domb et al. US. Patent no. 5,344,411, 6 September 1994.
28. Septacrol. Merck's Index, 4th edn. Rahway, NJ: Merck & Co., 1930, 456.
29. Cliver DO, Sarles WB, Foell WK, Goepfert JM. Biocidal effects of silver. Contract NAS 9-9300 Final Technical Report, University of Wisconsin, Accession Number N70 23888, NASA CR Number CR-108338, February 1970, 4-2-4-4.
30. Oka et al. US. Patent no. 5,516,519, 14 May 1996.
31. Oka H et al. Inactivation of enveloped viruses by a silver-thiosulfate complex. Metal-Based Drugs 1994; 1(5-6): 511.
32. Charney J, Fischer WPM, Sagin JF, Tytell AA. Inactivation of concentrated purified poliovirus suspensions. Ann NY Acad Sci 1960; 83: 649.
33. Cliver DO, Sarles WB, Foell WK, Goepfert JM. Biocidal effects of silver. Contract NAS 9-9300 Final Technical Report, University of Wisconsin, Accession Number N70 23888, NASA CR Number CR-108338, February 1970, 4-5-4-6.
34. Cliver DO, Sarles WB, Foell WK, Goepfert JM. Biocidal effects of silver. Contract NAS 9-9300 Final Technical Report, University of Wisconsin, Accession Number N70 23888, NASA CR Number CR-108338, February 1970, 4-6.
35. Montes LF, Muchinik G, Fox CL. Response to varicella-zoster virus and herpes zoster to silver sulfadiazine. Cutis 1986; 38(6): 3635.
36. Searle AB. The Use of Colloids in Health and Disease. New York: E. P. Dutton, 1919, 85.
37. Council on Pharmacy and Chemistry New and Nonofficial Remedies. Chicago: AMA, 1932, 401.
38. Ellerman-Eriksen S, Rungby J, Morgensen SC. Autointerference in silver accumulation in microphages without affecting phagocytic, migratory or interferon-producing capacity. Virchows Arch 1987; 53: 243.
39. Jansson G, Harms-Ringdahl M. Stimulating effects of mercuris and silver ions on the superoxide anion production in human polymorphonuclear leukocytes. Free Radic Res Commun 1993; 18(2): 87-98.
40. Feng QL, Wu J, Chen GO, et al. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res 2000; 52: 662-8.
41. Yudkin J. Enzymologia 1937-8; 2: 161-70.
42. Goetz A, Tracy RL, Harris FS. Oligodynamic effect of silver. In: Addicks L (ed.) Silver in Industry. New York: Reinhold, 1940, 402-3.
43. Agency for Toxic Substance and Disease Registry (ATSDR) US Public Health Service, Clement International Corporation, Under Contract no. 205-88-0608, Toxicological Profile for Silver, CAS# 7440-22-4, December 1990.
44. Von Nägeli C. On the oligodynamic phenomenon in living cells. Denkschriften der Schweiz Naturforsch Ges 1983; 33: 174-82.
45. Webster's Third International Dictionary, unabridged, (c) 1981, 1572.
46. Cliver DO et al. Biocidal effects of silver. Contract NAS 9-9300 Final Technical Report, University of Wisconsin, February 1970, 5.
47. In vitro investigations published on letterheads from Departments of Microbiology, Pathology, Infectious Diseases, Immunology, and Biology from such universities as: Johns Hopkins, Northwestern University Medical School, Queen's University, University of Arkansas for Medical Sciences, Georgetown University Medical Center, NYU Medical Center, University of Nebraska, University of Massachusetts 1996-1998.
48. Eichorn GL et al. Interaction of metal ions with biological systems, with special reference to silver and gold. Proceedings of the First International Conference on Gold and Silver in Medicine, Bethesda, MD, 13-14 May. Washington, DC: The Silver Institute, 1987, 4.
49. Bechhold H. Colloids in Biology and Medicine. New York: D. Van Nostrand, 1919, 366.
50. Bechhold H Zeitschr Physik Chemic 1907; 60: 313.
51. Bodansky M. Introduction to Physiological Chemistry. New York: John Wiley & Sons, 1934, 22-3.
52. Bechhold H. Colloids in Biology and Medicine. New York: D. Van Nostrand, 1919, 13.
53. Alexander J. Colloid Chemistry: An Introduction, With Some Practical Applications, 2nd edn. New York: D. Van Nostrand, 1924, 30.
54. Jirgensons B, Straumanis ME. A Short Textbook of Colloid Chemistry, 2nd rev edn. New York: Macmillan, 1962, 14.
55. Ostwald W. Handbook of Colloidal Chemistry, trans Fischer, Oesper and Berman. Philadelphia: P. Blakiston's Son & Co, 1915.
56. Kopaczewski W. The pharmacodynamics of colloids. In: Alexander J (ed.) Colloid Chemistry - Theoretical and Applied. New York: The Chemical Catalogue Co., 1928, Vol. 2, 962.
57. Acél D, Biochem Z 1920; 112: 23-32.
58. Goetz A. Water sanitation with silver. J Am Water Works Assoc 1943; 35: 579.
59. Rochart C, Uzdins K. Katadyn (silver preparation): clinical application. Schweiz Med Wochenschr 1947; 77: 1100-4.
60. Marino AA et al. The effects of selected metals on marrow cells in culture. Chem Biol Interactions 1974; 9: 217.
61. Berger TJ et al. Electrically generated silver ions: quantitative effects on bacterial and mammalian cells. Anti Microb Agents Chemother 1976; 9(2): 357-8.
62. Antelman M. US Patents: 5,017,295; 5,073,382; 5,078,902; 5,089,275; 5,098,582; 5,211,855; 5,223,149; 5,336,416; 5,336,499; 5,772,896.
63. Antelman M. Multivalent silver bacteriocides. Precious Metals 1992; 16: 151-63.
64. Antelman M. Anti-pathogenic multivalent silver molecular semiconductors. Precious Metals 1992; 16: 141-9.
65. Dean W et al. Reduction of viral load in AIDS patients with intravenous mild silver protein - three case reports. Clin Prac Altern Med 2001; Spring.
66. Antelman M. Silver (II, III) disinfectants. Soap/Cosmetics/Chemical Specialties 1994; March: 52-9.
67. Aiken C. In vitro MIC test against HIV-1, published account via email, AA-90 results, Vanderbilt University, School of Medicine, 16 December 1997.
68. Zhong-Yin Z et al. Zinc inhibition of renin and the protease from human immunodeficiency virus type 1. Biochemistry 1991; 30(36): 8717-21.
69. Hussain S et al. Cystine protects Na, K-ATPase and isolated human lymphocytes from silver toxicity. Biochem Biophys Res Commun 1992; 189: 1444-9.
70. Grier N. Silver and its compounds. In: Block S (ed.) Disinfection, Sterilization and Preservation. Philadelphia: Lea & Febiger, 1983, 380.
71. Coleman VR, Wilkie J, Levinson WE, Stevens T, Javetz E. Inactivation of herpesvirus hominis types 1 and 2 by silver nitrate in vitro and in vivo. Antimicrob Agents Chemother 1973; 4: 259.
72. Chang TW, Weinstein L. In vitro activity of silver sulfadiazine against herpesvirus hominis. J Infect Dis 1975; 132(1): 79-81.
73. Tokumaru T, Shimizu Y, Fox CL. Antiviral activities of silver sulfadiazine in ocular infection. Res Commun Chem Pathol Pharmacol 1974; 8: 151-8.
74. Shimizu F, Shimizu Y, Kumagai K. Specific inactivation of herpes simplex virus by silver nitrate at low concentrations and biological activities of the inactivated virus. Antimicrob Agents Chemother 1976; 10(1): 57-63.
75. Council on Pharmacy and ChemistryNew and Nonofficial Remedies. Chicago: AMA, 1932, 398-407.
76. Collargol. Merck's Index, 4th edn. Rahway, NJ: Merck & Co., 1930, 178.
77. Wood HC, LaWall CH. The Dispensatory of The United States of America, 21st edn. Philadelphia: J.B. Lippincott, 1926, 1476.
78. Goodman L, Gilman A. The Pharmacological Basis of Therapeutics: A Textbook of Pharmacology, Toxicology and Therapeutics for Physicians and Medical Students. New York: Macmillan, 1941, Table 45, 859.
79. Cliver DO, Sarles WB, Foell WK, Goepfert JM. Biocidal effects of silver. Contract NAS 9-9300 Final Technical Report, University of Wisconsin, Accession Number N70 23888, NASA CR Number CR-108338, February 1970, 29.
80. Cliver DO, Foell WK, Goepfert JM. Biocidal effects of silver. Contract NAS 9-9300 Final Technical Report, University of Wisconsin, Accession Number N71 24436, NASA CR Number CR-114978, February 1971, 4-7.
81. Cliver DO, Foell WK, Goepfert JM. Biocidal effects of silver. Contract NAS 9-9300 Final Technical Report, University of Wisconsin, Accession Number N71 24436, NASA CR Number CR-114978, February 1971, 2-5.
82. Simonetti N, Simonetti G, Bougonl F, Scalzo M. Electrochemical Ag+ for preservative use. App Environ Microbiol 1992; 58(12): 3834.
83. Goetz A. The oligodynamic effect of silver. In: Addicks L (ed.) Silver in Industry. New York: Reinhold, 1940, 409.
84. Voigt J. Das Kolloide Silver. Leopzig, 1929, 12ff.
85. Crocker JC, Grier DG. Interactions and dynamics in charge-stabilized colloid. MRS Bull 1998; 23: 24-31.
86. Vukovic VV, Nedeljkovic JM. Surface modification of nanometer-scale silver particles by imidazole. Langmuir 1993; 9(4): 980.
87. + Concentration Determination of Argentyn 23. Miami: Department of Marine Biology, University of Miami, 2003.
88. Dasmahapatra R. The important dots to know about the coronavirus family (http://www.stanford.edu/group/virus/corona/virushome.html) accessed 2 May 2003.
89. Zhang Z-Y et al. Zinc inhibition of renin and the protease from human immunodeficiency virus type 1, Biochemistry 1991; 30(36): 8719.
90. Cliver DO, Foell WK, Goepfert JM. Biocidal effects of silver. Contract NAS 9-9300 Final Technical Report, University of Wisconsin, Accession Number N71 24436, NASA CR Number CR-114978, February 1971, 4-1, 4-2, 5-3.
91. Milder. US Patent no. 5,322,520, 21 June 1994.
92. Liboff et al. US Patent no. 4,818,697, 4 April 1989.
93. Hink J, Jansen E. Are superoxide and/or hydrogen peroxide responsible for some of the beneficial effects of hyperbaric oxygen therapy? Med Hypotheses 2001; 57(6): 764-9.
94. Baugh MA. HIV: reactive oxygen species, enveloped viruses and hyperbaric oxygen. Med Hypotheses 2000; 55(3): 232-8.
95. Van den Blink B, van der Kleij AJ, Versteeg HH, Peppelenbosch MP. Immunomodulatory effect of oxygen and pressure. Comp Biochem Physiol A Mol Integr Physiol 2002; 132(1): 193-7.
96. Patrick TR, Manning GT, Oforsagd PA, Trapp WG. The correction of severe hypoxemia in adult respiratory distress syndrome with hyperbaric oxygenation (OHP). Chest 1970; 58(5): 483-90.
97. Reillo MR. Hyperbaric oxygen therapy for the treatment of debilitating fatigue associated with HIV/AIDS. J Assoc Nurses AIDS Care 1993; 4(3): 33-8.
98. Rogatskii GG et al. Effect of hyperbaric oxygenation on the corticosterone content of the blood in experimental acute respiratory distress syndrome. Biull Eksp Biol Med 1989; 107(5): 545-7.
99. Lustbader D, Fein A. Other modalities of oxygen therapy: hyperbaric oxygen, nitric oxide, and ECMO. Respir Care Clin North Am 2000; 6(4): 659-74.